Advanced search
Publication Cover
OncoImmunology Volume 8, 2019 - Issue 11
Submit an article Journal homepage
3,177
Views
40
CrossRef citations to date
0
Altmetric
Original Research

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity

Wei XieMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France
,
Sabrina ForveilleMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France
,
Kristina IribarrenMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-2930-8573
ORCID Icon,
Allan SauvatMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, FranceORCID Iconhttps://orcid.org/0000-0001-7076-8638
ORCID Icon,
Laura SenovillaMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France
,
Yan WangMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France
,
Juliette HumeauMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France
,
Maria Perez-LanzonMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-6306-6520
ORCID Icon,
Heng ZhouMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France
,
Juan F. Martínez-LealPharmaMar, Madrid, Spain
,
Guido KroemerMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France;Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China;Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon &
Oliver KeppMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6081-9558
ORCID Icon show all
Article: e1656502 | Received 20 May 2019, Accepted 13 Aug 2019, Published online: 05 Sep 2019

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Peng Liu, Jianzhou Chen, Liwei Zhao, Antoine Hollebecque, Oliver Kepp, Laurence Zitvogel & Guido Kroemer. (2022) PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. OncoImmunology 11:1.
Read now
Anette Sommer, Sandra Berndt, Hans-Georg Lerchen, Sabrina Forveille, Allan Sauvat, Dominik Mumberg, Guido Kroemer & Oliver Kepp. (2022) Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties. OncoImmunology 11:1.
Read now
Oliver Kepp, Laurence Zitvogel & Guido Kroemer. (2020) Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. OncoImmunology 9:1.
Read now
Juliette Humeau, Allan Sauvat, Oliver Kepp & Guido Kroemer. (2020) An unexpected link between immunogenic cell death and inhibition of gene transcription. OncoImmunology 9:1.
Read now

Articles from other publishers (36)

Hui Pan, Peng Liu, Liwei Zhao, Yuhong Pan, Misha Mao, Guido Kroemer & Oliver Kepp. (2024) Immunogenic cell stress and death in the treatment of cancer. Seminars in Cell & Developmental Biology 156, pages 11-21.
Crossref
Yunfei Chen, Hui Li & Yun Fan. (2023) Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy. Cancer Treatment Reviews 120, pages 102606.
Crossref
Guido Kroemer, Timothy A. Chan, Alexander M. M. Eggermont & Lorenzo Galluzzi. (2023) Immunosurveillance in clinical cancer management. CA: A Cancer Journal for Clinicians.
Crossref
Laura Moliner, Bingnan Zhang, Giuseppe Lamberti, Andrea Ardizzoni, Lauren A. Byers & Raffaele Califano. (2023) Novel therapeutic strategies for recurrent SCLC. Critical Reviews in Oncology/Hematology 186, pages 104017.
Crossref
Zheng Zhao, Yingbin Huang, Jing Wang, Hongsheng Lin, Fei Cao, Shuxin Li, Yin Li, Ziqian Li & Xuekui Liu. (2023) A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy. Biomaterials Science 11:6, pages 2200-2210.
Crossref
Lorenzo Galluzzi, Oliver Kepp, Erik Hett, Guido Kroemer & Francesco M. Marincola. (2023) Immunogenic cell death in cancer: concept and therapeutic implications. Journal of Translational Medicine 21:1.
Crossref
Shuai Zhang, Liwei Zhao, Hui Chen, Guido Kroemer, Peng Liu & Oliver Kepp. 2023. Radiation Oncology and Radiotherapy. Radiation Oncology and Radiotherapy 65 73 .
Samuel Rosner & Benjamin Levy. (2023) Relapsed small-cell lung cancer: a disease of continued unmet need. The Lancet Respiratory Medicine 11:1, pages 6-8.
Crossref
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F Smit, Alberto Chiappori, Maria Eugenia Olmedo, Ildiko Horvath, Christian Grohé, Anna F Farago, José Antonio López-Vilariño, Martin Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromir Roubec, Konstantinos Syrigos, Gregory Lo, Isidoro Barneto, Anthony Pope, Amparo Sánchez, Joseph Kattan, Konstantinos Zarogoulidis, Cornelius F Waller, Helge Bischoff, Oscar Juan-Vidal, Niels Reinmuth, Manuel Dómine & Luis Paz-Ares. (2023) Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. The Lancet Respiratory Medicine 11:1, pages 74-86.
Crossref
Juliette Humeau, Julie Le Naour, Guido Kroemer & Jonathan G. Pol. 2023.
Jiayang Cai, Yuanyuan Hu, Zhang Ye, Liguo Ye, Lun Gao, Yixuan Wang, Qian sun, Shiao Tong, Ji’an Yang & Qianxue Chen. (2022) Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma. Frontiers in Immunology 13.
Crossref
Rita De Sanctis, Flavia Jacobs, Chiara Benvenuti, Mariangela Gaudio, Raul Franceschini, Richard Tancredi, Paolo Pedrazzoli, Armando Santoro & Alberto Zambelli. (2022) From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds. Frontiers in Pharmacology 13.
Crossref
Daphne W. Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Slooff, Nura Tebayna, Joanne M. Mankor, Sara J. Baart, Rudi Hendriks, Anne-Marie C. Dingemans, Marcella Willemsen & Joachim G.J.V. Aerts. (2022) Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma. European Journal of Cancer 172, pages 357-366.
Crossref
Anna Manzo, Vincenzo Sforza, Guido Carillio, Giuliano Palumbo, Agnese Montanino, Claudia Sandomenico, Raffaele Costanzo, Giovanna Esposito, Francesca Laudato, Edoardo Mercadante, Carmine La Manna, Paolo Muto, Giuseppe Totaro, Rossella De Cecio, Carmine Picone, Maria Carmela Piccirillo, Giacomo Pascarella, Nicola Normanno & Alessandro Morabito. (2022) Lurbinectedin in small cell lung cancer. Frontiers in Oncology 12.
Crossref
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma L. McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Rebecca B. Watson, Yiyang Liu & Christopher J. O’Donnell. (2022) Synthetic Approaches to the New Drugs Approved During 2020. Journal of Medicinal Chemistry 65:14, pages 9607-9661.
Crossref
Joseph B. Hiatt, Perrin E. Romine & Daniel Y. Wu. (2022) Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens. Seminars in Oncology 49:3-4, pages 344-352.
Crossref
Apostolos Papachristos & Mark J. Ratain. (2022) Lurbinectedin-induced thrombocytopenia: the role of body surface area. Cancer Chemotherapy and Pharmacology 89:5, pages 573-575.
Crossref
Guido Kroemer, Claudia Galassi, Laurence Zitvogel & Lorenzo Galluzzi. (2022) Immunogenic cell stress and death. Nature Immunology 23:4, pages 487-500.
Crossref
Aleksandra Sochacka-Ćwikła, Marcin Mączyński & Andrzej Regiec. (2022) FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 27:7, pages 2259.
Crossref
Prince Singh Rajput, Sharib Raza Khan, Preeti Singh & Pooja A. Chawla. (2022) Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review. Anti-Cancer Agents in Medicinal Chemistry 22:5, pages 812-820.
Crossref
Lucia Musacchio, Carlo Maria Cicala, Vanda Salutari, Floriana Camarda, Maria Vittoria Carbone, Viola Ghizzoni, Elena Giudice, Camilla Nero, Maria Teresa Perri, Caterina Ricci, Francesca Tronconi, Giovanni Scambia & Domenica Lorusso. (2022) Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives. Frontiers in Oncology 12.
Crossref
Giulia Cerrato, Juliette Humeau, Allan Sauvat, Oliver Kepp & Guido Kroemer. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A 67 82 .
Yanhua Li, Xiaohan Liu, Xia Zhang, Wei Pan, Na Li & Bo Tang. (2021) Immunogenic cell death inducers for enhanced cancer immunotherapy. Chemical Communications 57:91, pages 12087-12097.
Crossref
Lijiao Wang, Rong Li, Chen Song, Yanli Chen, Haiyue Long & Lingling Yang. (2021) Small-Molecule Anti-Cancer Drugs From 2016 to 2020: Synthesis and Clinical Application. Natural Product Communications 16:9, pages 1934578X2110403.
Crossref
Lauren T. Shinn, Katrina A. Vo & David J. Reeves. (2020) Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer. Annals of Pharmacotherapy 55:9, pages 1172-1179.
Crossref
Worawat Songjang, Chatchai Nensat, Sutatip Pongcharoen & Arunya Jiraviriyakul. (2021) The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomedical Reports 15:4.
Crossref
Shuo Yuan, Yong-Qiang Luo, Jia-Hui Zuo, Hui Liu, Fang Li & Bin Yu. (2021) New drug approvals for 2020: Synthesis and clinical applications. European Journal of Medicinal Chemistry 215, pages 113284.
Crossref
Diego Cortinovis, Paolo Bidoli, Stefania Canova, Francesca Colonese, Maria Gemelli, Maria Luisa Lavitrano, Giuseppe Luigi Banna, Stephen V. Liu & Alessandro Morabito. (2021) Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma. Cancers 13:5, pages 1152.
Crossref
Théo Accogli, Mélanie Bruchard & Frédérique Végran. (2021) Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers 13:3, pages 373.
Crossref
Shetal Patel, William Jeffrey Petty & Jacob M. Sands. (2021) An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592110205.
Crossref
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel & Guido Kroemer. (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology 17:12, pages 725-741.
Crossref
Anthony Markham. (2020) Lurbinectedin: First Approval. Drugs 80:13, pages 1345-1353.
Crossref
Anna Maria Malfitano, Simona Pisanti, Fabiana Napolitano, Sarah Di Somma, Rosanna Martinelli & Giuseppe Portella. (2020) Tumor-Associated Macrophage Status in Cancer Treatment. Cancers 12:7, pages 1987.
Crossref
Juliette Humeau, Allan Sauvat, Giulia Cerrato, Wei Xie, Friedemann Loos, Francesca Iannantuoni, Lucillia Bezu, Sarah Lévesque, Juliette Paillet, Jonathan Pol, Marion Leduc, Laurence Zitvogel, Hugues de Thé, Oliver Kepp & Guido Kroemer. (2020) Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Molecular Medicine 12:5.
Crossref
Oscar Arrieta, Zyanya Lucia Zatarain-Barrón & Andrés F Cardona. (2020) New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer. The Lancet Oncology 21:5, pages 605-607.
Crossref
Zahra Asadzadeh, Elham Safarzadeh, Sahar Safaei, Ali Baradaran, Ali Mohammadi, Khalil Hajiasgharzadeh, Afshin Derakhshani, Antonella Argentiero, Nicola Silvestris & Behzad Baradaran. (2020) Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers 12:4, pages 1047.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.